These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 35366187)

  • 1. In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD.
    Mir SA; Dash GC; Meher RK; Mohanta PP; Chopdar KS; Mohapatra PK; Baitharu I; Behera AK; Raval MK; Nayak B
    Appl Biochem Biotechnol; 2022 Oct; 194(10):4292-4318. PubMed ID: 35366187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring binding stability of hydroxy-3-(4-hydroxyphenyl)-5-(4-nitrophenyl)-5,5a,7,8,9,9a-hexahydrothiazolo[2,3-b] quinazolin-6-one with T790M/L858R EGFR-TKD.
    Mir SA; Nayak B
    J Biomol Struct Dyn; 2023 May; 41(8):3702-3716. PubMed ID: 35343861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioinspired thiazolo-[2,3-b] quinazolin-6-one derivatives as potent anti-cancer agents targeting EGFR: their biological evaluations and in silico assessment.
    Mir SA; Mohanta PP; Meher RK; Baitharu I; Behera AK; Raut S; Nayak B
    Mol Divers; 2024 Aug; 28(4):2479-2494. PubMed ID: 37395840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis and Antitumor Activities of Novel Quinazolinone Derivatives as Potential EGFR Inhibitors.
    Wang J; Huang L; Chen X; Yuan Y; Sun J; Yang M
    Chem Pharm Bull (Tokyo); 2022; 70(9):637-641. PubMed ID: 36047235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural insights into conformational stability and binding of thiazolo-[2,3-b] quinazolinone derivatives with EGFR-TKD and
    Ahmad Mir S; Paramita Mohanta P; Kumar Meher R; Baitharu I; Kumar Raval M; Kumar Behera A; Nayak B
    Saudi J Biol Sci; 2022 Dec; 29(12):103478. PubMed ID: 36389208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of novel Thiazolo[5,4-b]pyridine derivatives as potent and selective EGFR-TK inhibitors targeting resistance Mutations in non-small cell lung cancer.
    Borude AS; Deshmukh SR; Tiwari SV; Kumar SH; Thopate SR
    Eur J Med Chem; 2024 Oct; 276():116727. PubMed ID: 39094428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR.
    Wassel MMS; Ammar YA; Elhag Ali GAM; Belal A; Mehany ABM; Ragab A
    Bioorg Chem; 2021 May; 110():104794. PubMed ID: 33735711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells.
    Zhang Y; Wang Q; Li L; Le Y; Liu L; Yang J; Li Y; Bao G; Yan L
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1205-1216. PubMed ID: 34074193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
    Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA
    Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis, Molecular Docking, and Biological Evaluation of Isatin-Based Fused Heterocycles As Epidermal Growth Factor Receptor Inhibitors.
    Kumar A; Kumar B; Bhatia R
    Assay Drug Dev Technol; 2023 Jul; 21(5):222-233. PubMed ID: 37439798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
    Yang X; Hou Z; Wang D; Mou Y; Guo C
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and
    Le Y; Gan Y; Fu Y; Liu J; Li W; Zou X; Zhou Z; Wang Z; Ouyang G; Yan L
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):555-564. PubMed ID: 31967481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis and Molecular Docking of Novel Quinazolinone Hydrazide Derivatives as EGFR Inhibitors.
    Fang ZY; Zhang YH; Chen CH; Zheng Q; Lv PC; Ni LQ; Sun J; Wu YF
    Chem Biodivers; 2022 Jun; 19(6):e202200189. PubMed ID: 35510593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, antitumor activity and molecular docking study of some novel 3-benzyl-4(3H)quinazolinone analogues.
    Al-Suwaidan IA; Abdel-Aziz AA; Shawer TZ; Ayyad RR; Alanazi AM; El-Morsy AM; Mohamed MA; Abdel-Aziz NI; El-Sayed MA; El-Azab AS
    J Enzyme Inhib Med Chem; 2016; 31(1):78-89. PubMed ID: 25815668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis, Cytotoxic Evaluation and Molecular Docking of New Fluoroquinazolinones as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects.
    Zayed MF; Ahmed S; Ihmaid S; Ahmed HEA; Rateb HS; Ibrahim SRM
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29891789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
    Aziz NAAM; George RF; El-Adl K; Mahmoud WR
    Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity.
    Sonousi A; Hassan RA; Osman EO; Abdou AM; Emam SH
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2644-2659. PubMed ID: 36146940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers.
    Soliman AM; Alqahtani AS; Ghorab M
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1030-1040. PubMed ID: 31074303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.